PRTK — Paratek Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $127.83m
- $343.47m
- $160.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.9% | ||
| Return on Equity | n/a | ||
| Operating Margin | -28.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.12 | 16.54 | 46.92 | 130.16 | 160.27 | 154.8 | 221.33 | 66.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Directors
- Michael Bigham CHM (63)
- Adam Woodrow PRE (54)
- Evan Loh CEO (62)
- William Haskel GCN (60)
- Randall Brenner OTH (48)
- Minnie Baylor-Henry IND (73)
- Thomas Dietz IND (57)
- Timothy Franson IND (69)
- Rolf Hoffmann IND (62)
- Kristine Peterson IND (62)
- Robert Radie IND (57)
- Jeffrey Stein IND (66)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- February 27th, 2001
- Public Since
- May 10th, 2006
- No. of Shareholders
- 79
- No. of Employees
- 268
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 57,282,239
- Address
- 75 Park Plaza, 4Th Floor, BOSTON, 02116
- Web
- https://www.paratekpharma.com/
- Phone
- +1 6178076600
- Auditors
- Ernst & Young LLP
Upcoming Events for PRTK
Q3 2023 Paratek Pharmaceuticals Inc Earnings Release
Similar to PRTK
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aptorum
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Paratek Pharmaceuticals share price?
As of Today at 19:17 UTC, shares in Paratek Pharmaceuticals are trading at $2.18. This share price information is delayed by 15 minutes.
How has the Paratek Pharmaceuticals share price performed this year?
Shares in Paratek Pharmaceuticals last closed at $2.18 and the price had moved by -7.63% over the past 365 days. In terms of relative price strength the Paratek Pharmaceuticals share price has underperformed the S&P500 Index by -20.7% over the past year.
What are the analyst and broker recommendations for Paratek Pharmaceuticals?
The overall consensus recommendation for Paratek Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Paratek Pharmaceuticals dividend yield?
Paratek Pharmaceuticals does not currently pay a dividend.
Does Paratek Pharmaceuticals pay a dividend?
Paratek Pharmaceuticals does not currently pay a dividend.
When does Paratek Pharmaceuticals next pay dividends?
Paratek Pharmaceuticals does not currently pay a dividend.
How do I buy Paratek Pharmaceuticals shares?
To buy shares in Paratek Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Paratek Pharmaceuticals?
As of the previous close price of $2.18, shares in Paratek Pharmaceuticals had a market capitalisation of $124.88m.
Where are Paratek Pharmaceuticals shares listed?
Here are the trading details for Paratek Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRTK
What kind of share is Paratek Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Paratek Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Paratek Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Paratek Pharmaceuticals is $3.10. That is 42.2% above the last closing price of $2.18.
Analysts covering Paratek Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.94 for the next financial year.
What is the trend in the Paratek Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Paratek Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -7.92%.
As of the last closing price of $2.18, shares in Paratek Pharmaceuticals were trading +0.32% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Paratek Pharmaceuticals PE Ratio?
The Paratek Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Paratek Pharmaceuticals?
Paratek Pharmaceuticals' management team is headed by:
- Michael Bigham - CHM
- Adam Woodrow - PRE
- Evan Loh - CEO
- William Haskel - GCN
- Randall Brenner - OTH
- Minnie Baylor-Henry - IND
- Thomas Dietz - IND
- Timothy Franson - IND
- Rolf Hoffmann - IND
- Kristine Peterson - IND
- Robert Radie - IND
- Jeffrey Stein - IND